scholarly journals Benign giant cell tumor of bone with pulmonary metastasis- report of two cases and review of literature

2017 ◽  
Vol 5 (3) ◽  
pp. 1131
Author(s):  
Geethu G. Nair ◽  
Rajan G. ◽  
Supriya N. K. ◽  
Sathi P. P.
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Pulmonary Metastasis ◽  
Past History ◽  
Bone Lesion ◽  
Giant Cells ◽  
Tumor Location ◽  
Cell Tumor ◽  
Sarcomatous Transformation ◽  
History Of

Tumors that are metastasizing generally considered as malignant. But there are exceptions. Giant cell tumor of bone is well known for its potential to metastasize without sarcomatous transformation. Potential of benign GCT to metastasize was first reported by Jaffe et al in 1940. Prevalence of pulmonary metastasis in benign GCT is between 1-9%. Factors favoring metastasis include recurrence of tumor, surgical manipulation of initial bone tumor, location of femur etc. Peripheral or basilar portion of pulmonary parenchyma is involved commonly. Eventhough death reported in 16-25% of cases, overall it has a favorable prognosis. Surgical resection is preferred treatment for pulmonary metastasis. In the present study 2 case studies were done. In 1st study 18 year old female, known case of GCT Lt tibia, with history of curetting and cementing presented with pain and swelling at same site and pulmonary metastasis 1 year later. Biopsy from initial as well as recurrent tumor confirmed benign GCT without any features of atypia, mitosis or necrosis. Aspirate from pulmonary lesion showed osteoclastic giant cells. No treatment given to metastatic deposits and is asymptomatic even though size of pulmonary lesions is increasing. And in second study a 22 year old female, with past history of GCT referred to our institution for evaluation of lung lesion detected in X-ray. Patient underwent metastatectomy here and histopathology was similar to that of bone lesion. There was no evidence of sarcomatous transformation both in initial and recurrent lesion. Patient is asymptomatic other wise and doing well.

scholarly journals Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Cory Julian Broehm ◽  
Erika L. Garbrecht ◽  
Jeff Wood ◽  
Therese Bocklage
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Malignant Transformation ◽  
Radiation Treatment ◽  
Cell Tumor ◽  
Rank Ligand ◽  
Review Of The Literature ◽  
Sarcomatous Transformation ◽  
History Of ◽  
Multiple Recurrences

Giant cell tumor (GCT) of bone is a generally benign, but often locally aggressive, neoplasm of bone, with a propensity for recurrence. Sarcomatous transformation is rare and typically occurs with a history of recurrences and radiation treatment. Denosumab, an inhibitor of the RANK ligand involved in bone resorption in GCT, is increasingly used in treatment of recurrent or unresectable giant cell tumor of bone. We report two cases of sarcomatous transformation of GCT to osteosarcoma in patients receiving denosumab. One was a 59-year-old male with a 12-year history of GCT and multiple recurrences taking denosumab for 2.5 years. The second case was in a 56-year-old male with a seven-year history of GCT taking denosumab for six months. Review of the literature shows one case report of malignant transformation of GCT in a patient being treated with denosumab. As the use of denosumab for treatment of GCT will likely increase, larger, controlled studies are needed to ascertain whether denosumab may play a role in malignant transformation of giant cell tumor of bone.

scholarly journals Disappearance of giant cells and presence of newly formed bone in the pulmonary metastasis of a sacral giant-cell tumor following denosumab treatment: A case report

2015 ◽  
Vol 11 (1) ◽  
pp. 243-246 ◽  
Author(s):  
TETSURO YAMAGISHI ◽  
HIROYUKI KAWASHIMA ◽  
AKIRA OGOSE ◽  
TARO SASAKI ◽  
TETSUO HOTTA ◽  
...  
Keyword(s):  
Case Report ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Pulmonary Metastasis ◽  
Giant Cells ◽  
Cell Tumor ◽  
Denosumab Treatment

A Comparison of Canine Giant Cell Tumor and Giant Cell Reparative Granuloma of Bone

1983 ◽  
Vol 20 (2) ◽  
pp. 215-222 ◽  
Author(s):  
F. J. Trigo ◽  
C. W. Leathers ◽  
D. F. Brobst
Keyword(s):  
Bone Formation ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Bone Lesion ◽  
Giant Cells ◽  
Cell Tumor ◽  
New Bone Formation ◽  
Giant Cell Reparative Granuloma ◽  
Pathologic Features ◽  
Lytic Bone Lesion

The clinical, radiographic, and pathologic features of a canine giant cell tumor of bone are compared with those of a giant cell reparative granuloma of bone. The giant cell bone tumor usually emerges from the epiphysis of long bones as a rapidly developing lytic bone lesion without periosteal new bone formation. The giant cell reparative bone granuloma originates preferentially in flat bones on the skull and mandible as a result of trauma-associated intraosseous hemorrhage, with new bone formation and sclerosis. Histologically, the neoplastic giant cells are scattered diffusely throughout the tissue, in contrast to the inflammatory giant cells that accumulate at the periphery of hemorrhages or around bone spicules. This peripheral accumulation is accompanied by a prominent collagenous and reticulum stroma. The morphologic and histochemical features of the giant cells can not be used as reliable tools to differentiate these two conditions.

Dendriform Pulmonary Ossification in a Patient With a Past History of Giant Cell Tumor in Femur

2008 ◽  
Vol 23 (1) ◽  
pp. 47-49 ◽  
Author(s):  
Susumu Kobayashi ◽  
Masaki Hara ◽  
Motoki Yano ◽  
Hisashi Tateyama ◽  
Yuta Shibamoto
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Past History ◽  
Cell Tumor ◽  
History Of

Giant cell tumor of the calvaria in a child

1994 ◽  
Vol 80 (1) ◽  
pp. 148-151 ◽  
Author(s):  
Lee Reed ◽  
Crystl D. Willison ◽  
Sydney S. Schochet ◽  
Joseph L. Voelker
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Stromal Cells ◽  
Giant Cells ◽  
Cellular Tissue ◽  
Cell Tumor ◽  
Content Type ◽  
History Of ◽  
Rare Lesion ◽  
Fine Print

✓ A giant cell tumor involving the vertex of the skull is described in a 3-year-old child with no history of head trauma. The mass was present approximately 4 months prior to resection. Microscopically, the lesion consisted of highly cellular tissue composed of oval to spindle-shaped stromal cells admixed with numerous multinucleated giant cells. Giant cell tumor of the skull is a rare lesion, usually involving the sphenoid or temporal bone in adults. The differential diagnosis is discussed with reference to the literature regarding giant cell lesions, especially of the cranium. The authors are unaware of previous reports of a similar lesion in this location in such a young child.

CLINICAL AND MORPHOLOGICAL CORRELATIONS AND HISTOPATHOLOGY OF JOINT DAMAGE IN PATIENTS WITH DIFFUSE-TYPE TENOSYNOVIAL GIANT CELL TUMOR

2019 ◽  
Vol 72 (12) ◽  
Author(s):  
Olena O Dyadyk ◽  
Anastasiia Hryhorovska
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Size ◽  
Giant Cells ◽  
Cell Tumor ◽  
Multinucleated Giant Cells ◽  
Diffuse Type ◽  
Association Coefficient ◽  
Mean Values ◽  
Tenosynovial Giant Cell Tumor

Introduction: Tenosynovial giant cell tumor (TSGCT) (synonym – pigmented villonodular synovitis) – is a rare benign proliferative lesion of the synovial sheath, localized in the joint capsule, bursa or tendon sheath and characterized by locally destructive growth. Depending on the prevalence within the joint elements, the presence of a capsule around the tumor, histophotographic features of cell structure and clinical behavior TSGCT can be divided to localized or diffuse type. The aim of the study was researching of histopathological properties of diffuse-type TSGCT, determine the parameters its morphological indicators and to find out the correlation between these morphological and clinical parameters. Materials and methods: The research material was used biopsy (resect) of pathological lesions from 50 patients who were diagnosed and histologically verified diffuse-type TSGCT. Microscopic examinations of the stained sections and their photo archiving were carried out with use of a Olympus-CX 41 light optical microscope. Group measurable parameters (mean values and Pearson tetrachoric index (association coefficient) were calculated in groups of comparison for morphological and clinical indices of TSGCT. The mean values were compared by Student’s test, P value of ≤0.1 was considered statistically significant. Results:Correlation analysis of indicators that accounted for the pairs of cases «clinic – morphology» revealed the relationships, that had the highest parameters of the association coefficient between such indicators: «presence of villous growths» - «severity of hemosiderosis» (if hypertrophied synovial villi available, with vascular injection and pronounced proliferation of synovial cells, there is also a significant accumulation of hemosiderin pigment); «presence of villous growths» - «type of predominant cellular proliferates» (if cells of TSGCT diffuse type consists of monotonous sheets of stromal cells, with uniform, oval to reniform nuclei, the proliferation of villi in synovial layer is non-distinctive); «presence of nodes» - «kind of stroma» (if nodes predominate, their histological structure is mainly represented by polymorphic clusters of synovitis cells in the form of cells, strands, chains, solid formations, among immature connective tissue with low hyalinosis); «cell size (area, cm²)» - «severity of haemosiderosis» and «cell size (area, cm²)» - «the number of multinucleated giant cells» (there is a pronounced deposition of pigment and accumulation of osteoclast-like multinucleated giant cells type, although usually their number is relatively small compared to the localized type of TSGCT). Conclusions: Morphological parameters, that we have identified, characterize pathological changes in the tissues of TSGCT; careful analysis of the frequency of their occurrence in the different comparison groups made it possible to establish intergroup differences and correlations between individual indicators, which were previously unknown or not obvious. Our study was determine to analyze of incidence rates and correlation relationships, revealed some previously unknown differences and dependencies that are important for understanding the pathogenesis, improvement of diagnosis and prognosis of diffuse-type TSGCT.

scholarly journals Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Andrew Chandler ◽  
Meredith K. Bartelstein ◽  
Tomohiro Fujiwara ◽  
Cristina R. Antonescu ◽  
John H. Healey ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Therapeutic Potential ◽  
Quantitative Polymerase Chain Reaction ◽  
Treatment Method ◽  
Giant Cells ◽  
Cell Tumor ◽  
Pcr Analysis ◽  
Increased Risk

Abstract Background Giant cell tumor of bone is a benign, locally aggressive neoplasm. Surgical resection is the preferred treatment method. However, for cases in which resection poses an increased risk to the patient, denosumab (anti-RANKL monoclonal antibody) is considered. Secukinumab is an anti-IL-17 antibody that is used in psoriatic arthritis to reduce bone resorption and articular damage. Case presentation One case of giant cell tumor of bone (GCTB) in a patient treated with secukinumab for psoriatic arthritis demonstrated findings significant for intra-lesional calcifications. Histologic examination showed ossification, new bone formation, and remodeling. A paucity of osteoclast type giant cells was noted. Real-time quantitative polymerase-chain-reaction (qRT-PCR) analysis revealed decreased osteoclast function compared to treatment-naive GCTB. Conclusions Secukinumab may play a role in bone remodeling for GCTB. Radiologists, surgeons, and pathologists should be aware of this interaction, which can cause lesional ossification. Further research is required to define the therapeutic potential of this drug for GCTB and osteolytic disease.

Giant Cell Poor Extra-Articular Diffuse-Type Tenosynovial Giant Cell Tumor With Extensive Desmin Expression: A Potential Diagnostic Pitfall With Cytogenetic Confirmation

2018 ◽  
Vol 27 (1) ◽  
pp. 59-61
Author(s):  
Liurka Lopez ◽  
Karen Schoedel ◽  
Ivy John
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Mononuclear Cells ◽  
Giant Cells ◽  
Cell Tumor ◽  
Diffuse Type ◽  
Tenosynovial Giant Cell Tumor ◽  
Diagnostic Pitfall

Diffuse-type tenosynovial giant cell tumor can rarely present as an entirely extra-articular mass, which can be misdiagnosed as a sarcoma especially when giant cells are absent, dominated by large dendritic mononuclear cells, and desmin expression is extensive.

scholarly journals Giant cell tumor stromal cells: osteoblast lineage-derived cells secrete IL-6 and IL-10 for M2 macrophages polarization

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9748
Author(s):  
Kuan Yang ◽  
Lihui Bao ◽  
Xiaoning He ◽  
Wanmin Zhao ◽  
Dongdong Fei ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Stromal Cells ◽  
Macrophage Polarization ◽  
Giant Cells ◽  
Interleukin 10 ◽  
Cell Tumor ◽  
M2 Macrophages ◽  
M2 Polarization ◽  
Macrophages Polarization

Background The giant cell tumor (GCT) is a benign tumor which consists of three types cells: mononuclear histiocytic cells (MNHCs), multinuclear giant cells (MNGCs), and GCT stromal cells (GCTSCs). Numerous studies claim that GCTSCs have mesenchymal stem cells (MSCs) characters and play an important role in osteoclastogenesis; however, there are no research studies concerning macrophage polarization among GCT, which can be regarded as an ingredient for tumor aggression. Method We tested the effect of GCTSCs from three GCT samples which were collected from patients on proliferation, apoptosis and polarization of macrophage. Result In this article, we verified that GCTSCs expressed MSCs markers and had higher proliferation and relative lower differentiation abilities compared with BMMSCs. What’s more, we found a higher proportion of M2 macrophages among neoplasm. Co-culturing GCTSCs with macrophages resulted in prominent macrophage M2 polarization and increased the release of IL-6 (Interleukin-6) and IL-10 (Interleukin-10)from GCTSCs. In conclusion, GCTSCs, as originating from MSCs, can secret IL-6 and IL-10, which may play a significant role in macrophage M2 polarization.

Sign in / Sign up

Export Citation Format

Share Document